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Systemic lupus erythematosus (SLE) is a fairly heterogeneous autoimmune disease of
unknown etiology that mainly affects women in the childbearing age. SLE is a prototype
type III hypersensitivity reaction in which immune complex depositions cause inflamma-
tion and tissue damage in multiple organs.Two distinct cell death pathways, apoptosis and
NETosis, gained a great deal of interest among scientists, since both processes seem to be
deregulated in SLE.There is growing evidence that histone modifications induced by these
cell death pathways exert a central role in the induction of autoimmunity. In the current
review, we discuss how abnormalities in apoptosis, NETosis, and histone modifications
may lead to a break of immunological tolerance in SLE.
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INTRODUCTION
Autoimmune disorders are disturbances of the immune system
that arise when the immune system responds to self. Immuno-
logical tolerance to self relies on the immune system to discrim-
inate self from non-self. Systemic lupus erythematosus (SLE) is a
systemic autoimmune disorder, in which primarily nuclear con-
stituents, i.e., DNA, histones, and ribonucleoproteins, are targeted
(1). In a substantial subset of SLE patients, autoantibodies also
target proteins from the cytoplasm of neutrophils (2). Since these
nuclear self-antigens are normally shielded from the extracellu-
lar space by the nuclear membrane and the cell membrane, the
key question is how these nuclear self-antigens are released and
become exposed to the immune system. Anno 2014 abnormalities
in two pathways of cell death, apoptosis and NETosis, are recog-
nized as central processes that provide nuclear autoantigens and
drive the autoimmune response in SLE (3).
TWO SOURCES OF AUTOANTIGENS IN SLE
For over 20 years, apoptosis has been considered as the major
source of autoantigens in SLE (4). Apoptosis is a highly orga-
nized and immunologically silent cell death pathway that plays an
important role in tissue homeostasis. In processes characterized
by a high-rate of tissue turnover, such as embryogenesis in human
development, apoptosis is a crucial mechanism that allows tissues
to remodel without triggering inflammation. Many cellular path-
ways and signals can activate proteolytic caspases to break down
the cell in a strictly controlled and fine-tuned manner that dis-
tinguishes apoptosis from any other form of cell death. Apoptosis
can be induced actively through ligation of cell surface receptors
such as Fas or TNFR or passively through lack of essential survival
signals. Apoptotic cells undergo a series of distinct morphological
changes, including cytoskeletal disruption, cell shrinkage, DNA
fragmentation, and plasma membrane blebbing (5). It has been
shown that many of the nuclear autoantigens targeted in SLE are
concentrated within apoptotic blebs (6, 7).
A specialized form of neutrophil cell death, termed NETosis,
has been described a decade ago (8). NETosis has been linked to
SLE as an additional source of autoantigens (9). During NETosis,
neutrophils extrude fibrillary networks composed of DNA, citrul-
linated histones, and granule peptides such as neutrophil elastase,
myeloperoxidase, and cathepsin G. These structures are termed
neutrophil extracellular traps (NETs) and serve to entrap and dis-
mantle not only extracellular bacteria, but also viruses, fungi, and
parasites (10–12). In addition to pathogens, sterile inflammatory
mediators such as monosodium urate (MSU) crystals, IL-8, IL-1β,
platelet-activating factor (PAF), and TNF-α have been reported to
induce NETosis (13). NETosis requires a very rapid disintegration
of the nuclear envelope, translocation of granule peptides to the
nucleus, PAD4-mediated citrullination of the chromatin, binding
of granule peptides to citrullinated chromatin, and finally rupture
of the plasma membrane (14). Where apoptosis is organized and
planned, NETosis seems much faster and less well-coordinated.
INCREASED CELL DEATH
MRL/lpr mice, the most commonly studied murine model for
lupus-like disease, develop an autoimmune disease that reflects
pathologies of human SLE, including lymph node enlarge-
ment, increased IgG levels, antinuclear autoantibody production,
glomerulonephritis, proteinuria, and development of skin lesions
(15). MRL/lpr mice express a defective form of the Fas receptor
that under physiological conditions stimulates cells to undergo
apoptosis. This initially led to the belief that SLE patients have a
similar defect in Fas-mediated apoptosis that underlies the failure
of self-tolerance. However, it has become clear that SLE is quite
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the opposite from being a disease with impaired apoptosis. Sub-
stantially, evidence correlates increased lymphocyte, neutrophil,
macrophage, and monocyte apoptosis directly to SLE disease
activity (16–19). It has been demonstrated that SLE serum has
a strong apoptosis-inducing capacity in macrophages, monocytes,
and lymphocytes from healthy donors (20). In addition, it has been
reported that autoreactive T cells show an increased expression
of the apoptotic ligands TRAIL, TWEAK, and FasL that directly
mediate the apoptosis of monocytes (21).
Since various bactericidal NET proteins were found to be
present at much higher levels in blood from patients with SLE com-
pared to healthy donor blood, enhanced NETosis is also implicated
in the genesis and/or amplification of the autoimmune response
in SLE (22–24). The pro-inflammatory cytokines IL-17A, TNF-
α, IL-1β, and IL-8 have all been reported to induce NETosis,
suggesting that NETs are extensively formed in an inflammatory
environment such as in SLE (25–27). Elevated levels of interferon-
alpha (IFN-α), a cytokine that under physiological conditions is
important for antiviral responses and immune activation, have
been correlated with disease activity in SLE (28). Recent evidence
indicates that NETosis is enhanced in SLE due to priming of neu-
trophils by IFN-α (29). Certain autoantibodies that are highly
present in the majority of SLE patients, such as anti-LL-37, anti-
HNP, and anti-RNP, can also stimulate neutrophils to produce
NETs in a FcγRIIa-dependent manner (30–32). Furthermore, a
distinct subset of neutrophils in SLE patients, so called low-density
granulocytes (LDGs), have been described with an increased NET-
releasing capacity due to their ability to synthesize IFN-α in an
autocrine manner (33).
Taken together, it is presumed that both apoptosis and NETo-
sis occur excessively in patients with SLE, which results in an
increased load of nuclear autoantigens. However, can this excessive
release of nuclear autoantigens explain the break of immunolog-
ical tolerance to nuclear antigens in SLE? Apoptosis and NETosis
are physiological forms of cell death. In our daily battle against
pathogens, we release NETs and between 50 and 70 billion cells die
daily due to apoptosis. Humans evolved redundant mechanisms
to clear apoptotic material and NETs. This clearance is usually
accompanied by secretion of anti-inflammatory cytokines (34).
Multiple groups tried to immunize mice with apoptotic cells/blebs
or NETs, but this never lead to considerable immune activation
(35, 36). Therefore, it can be concluded that increased apoptosis
or NETosis on its own is not sufficient to break immunological tol-
erance to nuclear autoantigens in SLE, and that additional factors
are required to turn apoptotic material or NETs into dangerous
triggers of autoimmunity.
CLEARANCE DEFICIENCY IN SLE
In 1980, it was for the first time described that macrophages
from SLE patients show an impaired phagocytic activity for yeast
(37). Later, it was described that the phagocytosis of autologous
apoptotic material by monocyte-derived macrophages is also dis-
turbed in about 50% of the SLE patients (38). This finding was
confirmed by other groups (18, 39). Interestingly, macrophages
differentiated from CD34 positive stem cells of SLE patients show
a different morphology than those generated from healthy donors;
they are relatively small and poorly ingest apoptotic material (40).
Furthermore, the amount of tingible body macrophages (TBMs)
found in germinal centers appears to be strongly reduced in SLE
patients (41). Apoptotic material in germinal centers is normally
internalized by TBMs. In SLE patients with a reduced number
of TBMs, apoptotic material was observed to be directly associ-
ated with the surface of follicular dendritic cells (FDCs), which
may provide survival signals for autoreactive B cells. Monocytes
and granulocytes from SLE patients display a reduced phagocytic
activity as well (42), which may be explained by the relative low
expression of the phagocytic receptor CD44 on both cell types (43).
In addition to well-functioning healthy phagocytes, serum
proteins have an important impact on the clearance of apop-
totic cells as well. Adequate removal requires a clear recogni-
tion of apoptotic cells, which is, in addition to the exposure of
phosphatidylserine on the outer leaflet of its plasma membrane,
strongly dependent on opsonizing proteins such as immunoglob-
ulin M (IgM), mannose-binding lectin (MBL), serum amyloid
P (SAP), C-reactive protein (CRP), and C1q. Numerous stud-
ies ascribe a role for these opsonins in the defective clearance of
apoptotic material in SLE. It has been shown that decreased IgM
levels and increased MBL levels correlate with an increased dis-
ease activity in SLE (44, 45), that administration of SAP and CRP
significantly delays disease onset and alleviates disease symptoms
(46, 47) and that C1q-deficient mice rapidly develop autoanti-
bodies against nuclear autoantigens (48). Polymorphisms at the
loci of the genes encoding these opsonins as well as the forma-
tion of autoantibodies against these opsonins are considered to
be the underlying cause for their absence or defective functioning
in SLE (49–52). Lastly, autoantibodies against pentraxin-related
protein PTX3, a cytokine-induced protein that is homologous to
CRPs and SAPs, appear to be frequently present in SLE patients
as well (53). In contrast to anti-CRP or anti-SAP autoantibodies,
anti-PTX3 autoantibodies are not associated with disease activity
but with the absence of glomerulonephritis and antiphospholipid
antibodies. The authors of this article suggest that PTX3 inhibits
the clearance of apoptotic material, which is counteracted by the
autoantibodies directed against them.
There is also evidence for an impaired clearance of NETs.
Deoxyribonuclease I (DNase I) plays a crucial role in the degrada-
tion of NETs, which is not surprising since the backbone of NETs
is composed of nuclear DNA. The relevance of proper DNase I
activity is reflected by the fact that DNase I-deficient mice develop
a syndrome that closely resembles to SLE (54). A considerable
number of SLE patients display a reduced DNase I activity (55).
These patients develop relative high titers of anti-dsDNA autoan-
tibodies and suffer from more severe symptoms. Low DNase I
activity in SLE may have a genetic cause (56) but can also be the
result of inhibitory molecules or anti-DNase I autoantibodies. In
a Taiwanese cohort, 62% of the SLE patients appeared to be pos-
itive for anti-DNase I autoantibodies compared to only 8% of
normal controls (57). Comparing sera from healthy donors and
patients with SLE in their capability of degrading NETs in vitro
revealed that 98.1% of the healthy donor sera degraded NETs nor-
mally, whereas a significant percentage of the SLE sera did not
(36.1%) (58). Interestingly, those patients who could not degrade
NETs developed lupus nephritis significantly more frequently than
those who could degrade NETs. Depleting autoantibodies from
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SLE sera considerably enhanced NET degradation, suggesting that
NET-bound autoantibodies inhibit NET degradation, most likely
by preventing the access for DNase I to the NET. In addition,
it was shown that NET-bound C1q also inhibits NET degrada-
tion (59) via the same mechanism. However, C1q seems to be a
double-edged sword in the removal of NETs: both recombinant
C1q and endogenous C1q derived from human serum were found
to opsonize NETs for their immunologically silent clearance by
macrophages (60). Lastly, it has been shown that the antimicrobial
peptides LL-37 and HMGB1 prevent NET degradation (61). This
latter observation is interesting, since it has been described that
these antimicrobial peptides are highly present in NETs from SLE
patients but not in those from healthy donors (32).
The contribution of intrinsic phagocyte defects and
absent/deficient serum factors to the impaired clearance of apop-
totic material and/or NETs in SLE seems clear. However, it is
believed that there are numerous additional factors and path-
ways that could play a role in the complex pathogenesis of SLE.
Although many different pathways may be deregulated, that all
lead to a comparable SLE phenotype, it is assumed that accumu-
lation of apoptotic material and NETs in tissues is the common
denominator between all patients with SLE (42). Nevertheless, the
question remains how such an accumulation of apoptotic mate-
rial and NETs can break immunological tolerance. After all, it
involves an accumulation of endogenous material that is not sup-
posed to elicit an autoimmune response. An important hypothesis
that gains growing support states that biochemical reactions, for
example cleavage by caspases or protein modifications by protein
modifying enzymes, lead to enrichment of protein modifications
in not efficiently cleared NETs or apoptotic cells (62). Certain
(combinations of) protein modifications may give rise to proteins
with neoantigens that behave as danger signals as well and thereby
are no longer perceived as endogenous and therefore have the
ability to initiate an autoimmune response. Neoantigens/danger
signals in NETs are directly exposed to the immune system, but
apoptotic blebs require to undergo secondary necrosis, a late apop-
totic stage characterized by loss of membrane integrity and leakage
of cellular constituents, for exposure of these neoantigens/danger
signals to the immune system (63). Neoantigens/danger signals
may be ingested, digested, and presented in an immunogenic
way by antigen-presenting cells in MHC class II to autoreactive
CD4+ T cells, who subsequently instruct autoreactive B cells to
produce autoantibodies against them. Alternatively, extracellular
autoantigens may be presented in MHC class I, via the mecha-
nism of cross-presentation, to autoreactive CD8+ T cells (64).
The concept of epitope spreading may ultimately lead to the wide
arsenal of autoantibodies that are characteristic for SLE. An impor-
tant group of proteins in which post-translational modifications
(PTMs) seem to play an important role in (the induction of)
autoimmune responses in SLE are histones (65).
HISTONE MODIFICATIONS RELATED TO SLE
Histones are a group of chromatin proteins that are abundantly
present in apoptotic blebs as well as in NETs. Anti-histone autoan-
tibodies are frequently found in SLE and are disease-specific (66).
Under physiological conditions, histones play a critical role in the
packaging of nuclear DNA. Eukaryotic cells possess five major
families of histones: H1/H5, H2A, H2B, H3, and H4. Histones
H2A, H2B, H3, and H4 are known as the core histones: two copies
of each of the four core histones assemble and are wrapped with
~146 bp of DNA to form the fundamental unit of chromatin
known as the nucleosome. Histones were originally thought to
solely function as a static scaffold for DNA packaging. Nowadays,
it is evident that histones are highly dynamic proteins, undergoing
multiple types of PTMs that regulate vital processes within the
cell such as transcription, replication, recombination, and DNA
repair. PTMs on histones mainly occur at the N-terminal tails and
include (but are not limited to) acetylation, methylation, ubiqui-
tination, poly(ADP-ribosyl)ation, and citrullination. These PTMs
are described below, with a focus on modifications associated with
cell death, which have been specifically related to autoimmune
situations such as SLE (Figure 1).
ACETYLATION
Acetylation and deacetylation of lysine residues at the N-terminal
tails of histones play an important role in the regulation of tran-
scription. Acetylation removes positive charges, thereby reducing
the affinity between histones and DNA and maintaining an open
and accessible conformation of DNA that is available for the bind-
ing of factors of the transcriptional machinery. Acetylation and
deacetylation reactions are catalyzed by enzymes with respectively
histone acetyltransferase (HAT) or histone deacetylase (HDAC)
activity. Various studies have investigated the significance of his-
tone acetylation in SLE. Hypoacetylation of histones H3 and H4
has been found in CD4+ T cells from SLE patients and spleno-
cytes from MRL/lpr mice (67, 68). Treatment of these MRL/lpr
mice with HDAC inhibitor trichostatin A reset the hypoacety-
lation of histones H3 and H4 and lead to an improved disease
phenotype. In addition, it has been shown that mice deficient
in HAT p300 develop an autoimmune disease similar to SLE in
its pathological manifestations (69). Altered histone acetylation
in unstimulated disease-relevant cells has been primarily linked
to an altered gene expression. In contrast to unstimulated cells,
apoptotic blebs or NETs from SLE patients contain hyperacety-
lated histones when compared to healthy donors (submitted data
of our group). Hyperacetylation of histones appears to occur early
during cell death. In the past, our group showed that hyper-
acetylated nucleosomes and acetylated histone peptides display an
enhanced capability in activating the immune system (70). Hyper-
acetylated nucleosomes were able to mature bone marrow-derived
DCs in vitro, which produced increased levels of IL-6 and TNF-α
compared with DCs cultured in the presence of normally acety-
lated nucleosomes. In addition, DCs cultured in the presence of
hyperacetylated nucleosomes were able to activate syngeneic T
cells. Furthermore, subcutaneous administration of a specific tri-
acetylated H4 peptide to pre-diseased MRL/lpr mice significantly
enhanced mortality, proteinuria, skin lesions, and glomerular IgG
depositions. In addition to a direct immunogenic affect, it is spec-
ulated that hyperacetylated histones in apoptotic blebs or NETs
enhance the recruitment and binding of“dangerous”antimicrobial
peptides such as LL-37, HMGB1, and HNPs. It has been shown that
these antimicrobial peptides display a high immunogenic poten-
tial in NETs (61). Our group showed that autoantibodies in SLE
patients frequently target acetylated epitopes in the N-terminal
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FIGURE 1 | Impaired clearance of apoptotic cells and/or NETs leads
to an enduring exposure of modified histones to the immune
system – insufficiently cleared apoptotic cells by macrophages
undergo secondary necrosis (SNe), thereby externalizing modified
autoantigens such as histones that become recognized as foreign
and dangerous by receptors of the innate immune system such as
toll-like receptors (TLR). Modified histones are also highly present in
NETs, that are also not properly cleared in SLE due to polymorphisms in
the DNase I gene (not shown), inhibitory anti-DNase I autoantibodies, or
NET-bound proteins such as HMGB1, LL-37, C1q (not shown), and
anti-chromatin autoantibodies that prevent the accessibility for DNase I
to the NET. The PTMs that are shown are associated with apoptosis
(blue), NETosis, or both (green) and are linked to the autoimmune
response in SLE.
tails of histones H2A, H2B, and H4. We characterized two mono-
clonal autoantibodies derived from a MRL/lpr mouse, KM-2 and
LG11-2, that recognize tri-acetylated H4 at lysines 8, 12, and 16
and acetylated H2B (K12), respectively (70, 71). Both autoanti-
bodies showed an increased reactivity with histones isolated from
apoptotic cells and also from NETs (submitted data of our group),
suggesting that these modifications are associated with apoptosis
and NETosis. Another study also showed that IgG autoantibodies
from histone-reactive SLE patients show high reactivity for acety-
lated H2B, whereas an increase in H4 acetylated at lysine 5 in NETs
was demonstrated as well (36).
METHYLATION
Histone methylation is the process by which methyl groups are
transferred by histone methyltransferases (HMTs) to lysine or argi-
nine residues of histones. Similar to acetylation, histone methyla-
tion regulates transcription and silencing of genes, depending on
the target sites. Di-methylation of H3 at lysine 9 and mono-, di-
, and tri-methylation of H4 at lysine 20 increases upon NETosis
(36). Methylation of histone H4 at lysine 20 has also been associ-
ated with apoptosis (72). Our group recently demonstrated that
autoantibodies present in the plasma from SLE mice and patients
preferentially recognize tri-methylated H3 at lysine 27 (73). This
latter reactivity was specific for SLE as there was hardly any reac-
tivity in plasma samples from patients with rheumatoid arthritis
(RA) or systemic sclerosis and healthy controls. Tri-methylation
of H3 at lysine 27 also increases upon NETosis, as demonstrated
by Liu et al. in ATRA-differentiated HL-60 cells (36). In our hands,
this epitope is also highly present in NETs formed by primary neu-
trophils (submitted data of our group). Methylation of histones
seems to be associated with an increased immunogenic poten-
tial of chromatin, similar to the aforementioned acetylation of
histones, but additional research is required to unravel the exact
mechanisms.
UBIQUITINATION
The process of ubiquitination involves the conjugation of ubiq-
uitin to other cellular proteins, thereby regulating a broad range
of eukaryotic cell functions such as apoptosis, antigen process-
ing, DNA transcription and repair, cell division, and immune
responses. Ubiquitination may signal proteins for their degrada-
tion via the proteasome, alter their cellular location, affect their
activity, and promote or prevent protein–protein interactions. In
human, 10% of all H2A proteins is monoubiquitinated at lysine
119 (UH2A) (74). Autoantibodies against UH2A are frequently
found in SLE and appear to be disease-specific (75). Between 60
and 70% of SLE patients are positive for anti-UH2A autoantibod-
ies, compared to 10% of patients with systemic sclerosis. In RA,
juvenile chronic arthritis, or Sjögren’s syndrome, these autoanti-
bodies are virtually absent. Deposits of UH2A have been identified
in more than 50% of the renal biopsies from SLE patients with
glomerulonephritis (76). Disappearance of UH2A (deubiquiti-
nation) is linked to late apoptotic processes and is likely to be
disturbed in SLE (77, 78). Polymorphisms in the TNFAIP3 gene,
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the gene that encodes for the deubiquitinating enzyme A20, are
highly associated with SLE (79). These polymorphisms lead to a
reduced expression of A20 and result in increased ubiquitination,
as demonstrated by Jury et al. in T cells from SLE patients (80).
Due to the inhibitory effect of A20 on the NFκB signaling pathway,
TNFAIP3 polymorphisms also cause hyperactive NFκB signaling.
The ribonucleoprotein SSA/Ro is, in addition to UH2A, also a
ubiquitinated protein that is frequently target of SLE autoantibod-
ies (81). Hyperubiquitinated histones released from late apoptotic
cells or NETs are likely to display an increased antigenicity and
immunogenicity, but the underlying mechanisms are not fully
elucidated yet.
POLY(ADP-RIBOSYL)ATION
Poly(ADP-ribosyl)ation of proteins involves the addition of
poly(ADP-ribose) moieties (PARs), mediated by poly(ADP-
ribose) polymerases (PARPs). These reactions are involved in cell
signaling and the control of many cell processes, including DNA
repair, telomere maintenance, and apoptosis. Autoantibodies that
bind to PARs or to the two zinc finger motifs of PARPs are fre-
quently found in patients with autoimmune rheumatic and bowel
diseases, and SLE (82–84). Anti-PARP autoantibodies do not sig-
nificantly affect the enzyme activity of PAPRs, but prevent the
cleavage of PARPs by caspase-3 (85). This cleavage is important in
the proper execution of apoptosis. Inefficient cleavage of PARPs
has shown to prolong cell survival ex vivo and may therefore
cause failure to eliminate autoreactive lymphocytes and sustain
autoimmune stimulation. Anti-PARP autoantibodies can pene-
trate cells in relative late stages of apoptosis, thereby neutralizing
PARP activity. As a result of energy depletion, prolongation of
cell survival may ultimately result in necrosis, thereby releasing
poly(ADP-ribosyl)ated proteins that may possess high antigenic
and immunogenic potential. It has been shown that oligo(ADP-
ribosyl)ated histones are involved in the production of anti-PARP
autoantibodies in SLE patients (86). Lysine 13 of H2A, lysine 30 of
H2B, lysine 37 of H3, and lysine 16 of H4 have all been identified
as ADP-ribose acceptor sites (87).
CITRULLINATION
Citrullination (also known as deamination) involves the conver-
sion of arginine residues into citrulline, a process catalyzed by
enzymes known as peptidylarginine deiminases (PADs). While
most of the previously discussed PTMs are reversible and asso-
ciated with reversible events involved in signal transduction, cit-
rullination is not reversible. Citrullination has an important role
in the normal function of the immune system, skin keratinization,
the insulation of neurons, and the plasticity of the central ner-
vous system including its essential role in gene regulation. In RA,
autoantibodies to citrullinated proteins (anti-CCP) is considered
a key pathogenic event. The presence of anti-CCP autoantibod-
ies is a powerful biomarker that allows the diagnosis of RA to
be made at a very early stage (88). Many groups investigated the
role of NETs in the production of anti-CCP autoantibodies in
RA- and PAD4-mediated citrullination of histones, which appear
as the essential initiator for NETosis via decondensation of the
chromatin (89). Khandpur et al. correlated accelerated NETosis in
RA with anti-CCP levels (25), but this correlation has raised the
following question: if NETosis, initiated by citrullination of his-
tones, plays a pathogenic role in both RA and SLE, then why is the
presence of anti-CCP autoantibodies highly sensitive and specific
for RA only and not for SLE? Hence, anti-CCP autoantibodies are
present in only 10–30% of SLE patients compared to 80–90% of
RA patients (90, 91). Interestingly, SLE patients with arthritis are
significantly more positive for anti-CCP than those without arthri-
tis, suggesting that these autoantibodies have a predictive value for
the development of arthritis in SLE (92). A groundbreaking pub-
lication by Romero et al. questions the contribution of NETs to
anti-CCP production (93). This group showed that proteins highly
present in RA synovial fluid cells become hypercitrullinated due
to membranolysis of these cells by perforins and the membrane
attack complex (MAC) of the complement system. This membra-
nolysis results in a massive calcium influx that activates PADs to
citrullinate various substrates, such as vimentin, fibronectin, and
α-enolase. Although it seems that citrullinated histones, present in
NETs and to a lesser extent also in apoptotic blebs, do not exert an
important role in the induction of anti-CCP autoantibody pro-
duction, they may still play a pathogenic role. To our knowledge,
studies about the immunogenic effect of citrullinated histones in
NETs or apoptotic cells have not yet been conducted. The antimi-
crobial peptide LL-37 is highly present in NETs from SLE patients
and has recently been found to be also a substrate of PADs (94).
Citrullinated LL-37 showed to be more chemotactic to PBMCs and
more pro-inflammatory compared to unmodified LL-37. Compa-
rable results may also hold for citrullinated histones, although
additional research is required.
CONCLUDING REMARKS
The exact etiopathogenesis of SLE is far from understood. Many
different environmental factors are believed to act together to
induce SLE in those who are genetically predisposed. There is a
growing body of evidence that shows that disturbances in two
cell death pathways, apoptosis and NETosis, are causative for ini-
tiating the disease and amplifying existing disease. However, the
relative contribution of apoptosis and NETosis to the genesis of
SLE is unclear and is likely to differ from patient to patient.
Regardless of this, it is assumed that disturbances in both cell
death pathways interact with each other and create multiple pos-
itive feedback loops that lead to chronification or exacerbation of
the disease (Figure 2). Despite the heterogeneity in the underly-
ing (molecular) defects and pathways that cause SLE, it appears
that accumulation of apoptotic material and NETs in tissues is
the common denominator between all patients with SLE. Enrich-
ment of protein modifications, and in particular specific histone
modifications, in not efficiently cleared apoptotic cells or NETs
may generate neoantigens/danger signals with an increased anti-
genic and immunogenic potential. In addition to PTMs, another
process to be considered in the generation of neoantigens/danger
signals is proteolytic cleavage of histones and other chromatin-
associated proteins by for example caspases, neutrophil elastase,
and/or cathepsins. It is conceivable that chromatin-derived PTMs
and/or cleavage products, related to apoptosis and/or NETosis,
specifically ligate to receptors on antigen-presenting cells, thereby
activating these cells and resulting in their immunogenic presen-
tation. Improving or intensifying the clearance of apoptotic cells
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FIGURE 2 | Positive feedback loops arising from the interaction
between apoptosis and NETosis, leading to chronification and/or
exacerbation of the disease – modified autoantigens, derived from
apoptotic cells, may be presented by antigen-presenting cells to
autoreactiveT cells, which can lead to production of autoantibodies by
B cells, including anti-dsDNA or anti-RNP antibodies. These
autoantibodies can induce NETosis or form immune complexes with their
antigen. Immune complexes deposit on basal membranes, and incite a
local inflammation (organ damage), or stimulate plasmacytoid dendritic cells
to produce IFN-α and other pro-inflammatory cytokines. Pro-inflammatory
cytokines such as IL-1β, TNF-α, or IFN-α induce NETosis or prime neutrophils
for NETosis: NETs may serve as B cell autoantigens and lead to further
autoantibody production or directly cause organ damage. Proteins from
neutrophil granules, present in NETs, have shown to be highly toxic to
glomerular structures and endothelium. Endothelial or glomerular damage
causes further production of pro-inflammatory cytokines and leads to a new
load of apoptotic cells.
and/or NETs may prevent the formation of immunogenic nuclear
autoantigens. In addition, neutralizing and tolerizing strategies
using specific chromatin-derived PTMs and/or cleavage products
related to apoptosis and/or NETosis may represent future therapies
for SLE.
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